Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Lexaria Bioscience in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.
Current Consensus is
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in Lexaria Bioscience. This N/A consensus rating has held steady for over two years.
Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods. It operates in two segments, Intellectual Property Licensing and Consumer Products. The company develops and licenses DehydraTECH, a patented lipid nutrient infusion technology that improves taste, rapidity, and delivery of bioactive compounds that include cannabinoids, vitamins, NSAIDs, nicotine, and other molecules. It is also involved in the development, production, and distribution of enhanced functional food and supplement products under the ViPova and Lexaria Energy brands. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was founded in 2004 and is based in Kelowna, Canada.
Read More
